№ lp_2_3_38036
File format: docx Character count: 42486 File size: 160 KB
Scientific research article presenting a multivariate gene expression analysis of diagnostic biopsies from classical Hodgkin Lymphoma patients to derive and validate a predictive model of interim FDG-PET metabolic response after two cycles of ABVD chemotherapy.
Authors: Luminari S; Donati B; Casali M; Valli R; Santi R; Puccini B; Kovalchuk S; Ruffini A; Fama A; Berti V; Fragliasso V; Zanelli M; Vergoni F; Versari A; Rigacci L; Merli F; Ciarrocchi A
Affiliations: Hematology Unit, AUSL-IRCCS, Reggio Emilia; University of Modena and Reggio Emilia; Laboratory of Translational Research, AUSL-IRCCS, Reggio Emilia; Nuclear Medicine, AUSL-IRCCS, Reggio Emilia; Pathology Unit, AUSL IRCCS, Reggio Emilia; Pathology Unit, Careggi University Hospital, Firenze; Hematology, AOSP Careggi, Firenze; Gruppo Amici Dell’Ematologia Foundation (GrADE); Nuclear Medicine, University of Firenze; Hematology and Stem Cell Transplant AO San Camillo Forlanini, Roma
Corresponding authors: Alessia Ciarrocchi; Stefano Luminari
Country: Italy
Institutions: AUSL-IRCCS Reggio Emilia; University of Modena and Reggio Emilia; Careggi University Hospital Firenze; University of Firenze; AO San Camillo Forlanini Roma
Medical field: Hematology; Oncology; Molecular diagnostics
Disease: Classical Hodgkin Lymphoma
Treatment regimen: ABVD
Study population: Previously untreated stage I–IV classical Hodgkin Lymphoma patients
Sample size: 238 patients (121 training set; 117 validation set)
Methodology: Digital gene expression profiling (NanoString Technology); multivariate regression analysis; five-point Deauville scale assessment
Genes analyzed: 770 immune-related genes
Primary endpoint: Prediction of interim FDG-PET positivity after two cycles of ABVD
Running title: Gene predictive model for interim PET in Hodgkin Lymphoma
Keywords: Hodgkin Lymphoma; metabolic response; interim PET; gene-based predictive model; tumor microenvironment
Word count: 4124
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Possible Side Effects of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine, (ABVD) (Table Version Date: March 17, 2022)
Year: 2022
Type of document: Medical Information
Target Audience: Healthcare professionals and patients receiving ABVD chemotherapy
Subject: Chemotherapy side effects
Date of approval: March 17, 2022
Changes date: N/A
Supplemental Digital Content: Overall survival (A) and Progression Free Survival (B) in 193 patients with stage II/III/IV nodular lymphocyte-predominant Hodgkin lymphoma who received chemotherapy according to stage and Rituximab.
Year: Not specified
Region / City: Not specified
Theme: Oncology, Hematology
Document Type: Scientific Research
Organization / Institution: Not specified
Author: Not specified
Target Audience: Medical professionals, researchers
Action Period: Not specified
Approval Date: Not specified
Date of Changes: Not specified
Topics: expression-based ABVD Hodgkin